Medscape

ECG Challenge: Gallbladder Inflammation and Palpitations

Several hours after admission, he states that he is experiencing palpitations and an ECG is obtained. The initial part of the ...

Ventricular Tachycardia Market to Hit $22.28 Billion by 2032, at a CAGR of 5.3%, says Coherent Market Insights

The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...
PharmiWeb

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...
Healio

FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
MedPage Today

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...
TCTMD

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

The US Food and Drug Administration has approved etripamil nasal spray (Cardamyst) for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), drugmaker Milestone ...
Nasdaq

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first ...
Yahoo Finance

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...
The Globe and Mail

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Scientific Research Publishing

Pachchipulusu, V.K., Paudel, Y., Patel, A., Najam, B., Desai, H.N., Illango, J., et al. (2023) Efficacy of Adenosine versus Verapamil in Terminating Acute Attacks of Paroxysmal ...

ABSTRACT: Paroxysmal supraventricular tachycardia (PSVT) is a common rapid arrhythmia observed in clinical settings, characterized by abrupt and sustained episodes lasting minutes to hours. It ...
Monthly Prescribing Reference

Rapiblyk Now Available to Treat Supraventricular Tachycardia

Credit: AOP Health. Rapiblyk is supplied as a lyophilized powder containing 280mg of landiolol (equivalent to 300mg of landiolol HCl) in a single-dose vial. It is intended for use in intensive care, ...